Established in 2001, Mycenax is a dedicated CDMO specializing in process development and GMP production for innovative biologics. With our extensive expertise in developing biologic products, we offer a comprehensive range of solutions, including mAb, bi-specific (BsAb), multi-specific antibodies, ADCs/PDCs, plasmid DNA, fusion proteins, vaccines and cell therapy products. Leveraging our advanced platforms and PIC/S GMP-compliant manufacturing facilities, we provide time- and cost-effective one-stop services to clients worldwide.
There is no investment information
No recent news or press coverage available for Mycenax Biotech Inc..